trial · primary record
Telisotuzumab Adizutecan
Metastatic Colorectal Cancer
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 390 |
| Primary completion | 2028-04 |
| Primary endpoint | Objective Response (OR) as Assessed by the Investigator confirmed complete response (CR) or partial response (PR) as assessed by the investigator per response evaluation criteria in solid tumors (RECIST), version 1.1. |
| Registry ID | NCT06820463 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:31.192Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06820463
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.